MC38 Syngeneic Model Service for Colon Cancer

The MC38 syngeneic model of colon cancer grows a mismatch-repair-deficient, hypermutated murine adenocarcinoma in fully immunocompetent C57BL/6 hosts, making it the benchmark platform for checkpoint-inhibitor and combination immunotherapy research. Alfa Cytology delivers the complete MC38 workflow—source-verified cell banking, subcutaneous or colon-wall implantation, volume-balanced randomization, scheduled dosing and immune-rich endpoint analysis—giving sponsors decision-ready preclinical datasets shaped to their program, strictly within a preclinical scope.

Overview of MC38 Syngeneic Model for Colon Cancer

MC38 entered the literature in 1975, when Corbett and colleagues at the NCI described a transplantable colon adenocarcinoma induced in a female C57BL/6 mouse by 1,2-dimethylhydrazine—part of the same carcinogen program that produced its BALB/c cousin CT26. What sets MC38 apart is its molecular engine: defects in the mismatch-repair machinery (mutations in POLD1 and MSH3) render it microsatellite-instability-high, carrying a mutational burden that dwarfs most murine lines and faithfully emulates the CMS1 subtype of human colorectal cancer. Its oncogenomics are equally distinctive—Kras is wild type while Trp53, Smad4, Smad2, Pten, Acvr2A, Tgfb2 and Braf are mutated, Axin2 is truncated and Wnt/β-catenin and EGFR pathways are engaged—and that hypermutation expresses itself immunologically: catalogued neoantigens include ADPGK and REPS1 (Yadav and colleagues), with Rpl18 dominating the response in the Leiden stock. The line also has a vaccine pedigree—interleukin-12 gene-transduced MC38 was rejected and conferred resistance to rechallenge in the landmark study—and engineered derivatives such as MC38-OVA, human-PD-L1 transfectants for transgenic hosts, and CD46-expressing variants for oncolytic measles platforms extend its reach.

Fig 1. Schematic workflow of the orthotopic MC38-GFP syngeneic colon cancer model — cell injection into injured cecal mucosa, colonoscopy or IVIS monitoring from 1 week to 3 months, followed by tissue fixation, staining and data analysis. (Richon, Sophie, et al., 2023)

In practice, five million cells in the flank produce tumors that double roughly every four days, are randomized at 100–150 mm³, and fit a three-week dosing window—and the model answers treatment with rare generosity: anti-PD-1 yields frequent partial responses with complete regressions in subsets, anti-CTLA-4 shows clear monotherapy activity, and the combination of both is among the most reproducible synergies in preclinical oncology, with anti-CD40 agonists and CCR8-directed Treg depletion also validated here. An orthotopic colon-wall variant grows more aggressively and remains PD-1 sensitive, while serial in vivo selection has generated anti-PD-1-resistant lines whose lesions flip to PMN-MDSC predominance—a mechanistically rich system for resistance research. Response itself is host-context-sensitive: antibiotic exposure measurably blunts checkpoint efficacy, underscoring microbiome influences. Two caveats deserve emphasis: not all MC38 stocks are equal, as Leiden-derived and vendor-derived lines diverge in transcriptome, mutanome and neoantigen expression, so source verification is essential; and the brisk kinetics compress windows for slower agents. Within those boundaries, no syngeneic colon model is better characterized or more publication-dense for preclinical immuno-oncology.

Cell Line Information: MC38

Key characteristics of MC38 and its commonly used derivatives are summarized below.

Our Services

With in vivo oncology specialists guiding each stage and flow cytometry, bioluminescence imaging and digital pathology in-house, Alfa Cytology shapes every MC38 engagement around the sponsor’s question—controlling cell source and passage, calibrating inoculum and randomization thresholds, and pairing dosing with deep immune profiling so the model’s immunogenic firepower resolves into clean, decision-grade preclinical data.

Workflow of MC38 Syngeneic Model Construction

Construction of the MC38 syngeneic model is an implantation workflow whose quality rests on source-verified cells, vigorous C57BL/6 recipients, standardized technique and a disciplined measurement cadence. A standard engagement proceeds as follows:

1. Source and qualify cells: MC38 or MC38-luc stocks are cleared by mycoplasma PCR and identity verification, with the supplier source documented (given documented stock divergence in neoantigen expression); luciferase expression is titrated in vitro with D-luciferin before expansion.
2. Prepare recipients: C57BL/6 mice (typically 6–8 weeks old) complete acclimation and health screening and are individually marked before implantation; antibiotic-free husbandry is maintained where checkpoint studies are planned.
3. Prepare the inoculum: log-phase cells are harvested, washed, counted and resuspended in PBS (commonly 2.5 × 10⁷/mL for a 0.2 mL dose).
4. Implant: 5 × 10⁶ cells are injected subcutaneously into the flank with a fine needle at a fixed anatomical site; a colon-wall orthotopic variant is offered where gut-context biology is the question.
5. Randomize: when tumors reach ~100–150 mm³, animals are assigned to groups balanced by tumor volume and body weight.
6. Dose and follow: test articles (including checkpoint agents and combinations) are administered on schedule; tumors are measured with calipers two to three times weekly (volume typically π/6 × length × width × height), with bioluminescence substituted or added for labeled cohorts; body weight, clinical status and survival are logged in parallel.
7. Terminate and analyze: tumors are resected and weighed; tissues enter histopathology, immunohistochemistry and multiparameter flow-cytometric profiling of T cells, Tregs, MDSCs and macrophages; cured-animal rechallenge arms can be added for vaccine-style readouts.

Fig 2. MC38 Syngeneic Model construction workflow.

Case Study-MC38 Syngeneic Model Development

Alfa Cytology keeps an active file of preclinical case studies on the MC38 platform: establishment-phase optimization of inoculum, implant site and randomization threshold; in vivo growth tracking by caliper or bioluminescence; checkpoint, combination and myeloid/Treg-targeting intervention studies; and deep tumor-immune profiling with histological confirmation. Representative growth curves, immune-profiling datasets and endpoint summaries can be shared upon request and will be updated as new programs conclude.

Why Choose Alfa Cytology?

MC38 is the most benchmarked syngeneic line in oncology, and benchmarking only works when every rung of the workflow is controlled—which is where Alfa Cytology concentrates its effort:

• Documented cell sourcing with supplier traceability, acknowledging the published stock-to-stock divergence in neoantigen expression.
• Uniform, high-take flank implantation with a colon-wall orthotopic option and fixed randomization thresholds.
• An MSI-high, immunogenic tumor with reproducible anti-PD-1/anti-CTLA-4 responsiveness for clean benchmark data.
• Antibiotic-aware husbandry that protects checkpoint responses from microbiome confounding.
• Deep immune endpoints—multiparameter flow cytometry, IHC and digital pathology—matched to the model’s immunology.
• Resistant-model capability through in vivo selection for mechanistic resistance studies.
• One accountable project contact with milestone-by-milestone visibility.
• A strictly preclinical scope—every study is planned, executed and reported as non-clinical research.

Contact Us

Interested in the MC38 syngeneic colon cancer model for your next preclinical program? Reach out to us with your agent, timeline and endpoint wish-list, and the Alfa Cytology team will respond with a customized plan covering model setup, dosing strategy and analysis workflow—contact us today and move your program forward with confidence.

For research use only. Not intended for any clinical use.